1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

Sawai Sets Upsher-Smith $50m+ Target For Former Reddy’s Brands

 
• By Aidan Fry

Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.

50M
Sawai Believes Its Upsher-Smith Unit In The US Could More than Double Annual Sales Of Two Sumatriptan Brands Acquired For Dr Reddy's To More Than $50m • Source: Shutterstock

Sawai Pharmaceutical expects its Upsher-Smith affiliate, by its 2022-2023 financial year, to generate more than $50m in annual sales from two migraine brands recently acquired from Dr Reddy’s. That will be well over double the less than $20m that the Japanese group expects from the Zembrace SymTouch and Tosymra sumatriptan brands in its current financial year ending on 31 March 2020.

Upsher-Smith paid Reddy’s $70m upfront, plus another $40.5m in near-term milestones and financial considerations, for the Zembrace SymTouch 3mg injectable, which is already on the US market, and the Tosymra 10mg nasal spray, which is not. Sawai said Upsher-Smith had scheduled a launch for the Tosymra migraine remedy before the end of this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.